Bassotti G¹, Usai Satta P², Bellini M³. Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):257-262. doi: 10.1080/17474124.2019.1568238. Epub 2019 Jan 23.

Author information

1 a Gastroenterology & Hepatology Section, Department of Medicine , University of Perugia Medical School , Perugia , Italy.

2 b Gastrointestinal Unit , "G. Brotzu" Hospital , Cagliari , Italy.

3 c Gastrointestinal Unit, Department of Translational Research and New Technologies in Medicine and Surgery , University of Pisa , Pisa , Italy.

Abstract

Prucalopride is a prokinetic drug, that has been commercially available in recent years for the treatment of chronically constipated patients. In this update of a previous 2016 article, we reviewed the more recent data supporting its role in the treatment of constipation and constipation-associated conditions. Areas covered: We carried out an extensive literature review on the effects of prucalopride for the years 2012-2018 by means of scientific databases and manual research. More evidence was found on its possible therapeutic role in conditions in which constipation plays a role as an associated symptom, such as opioid-induced constipation, constipation-predominant irritable bowel syndrome, post-operative ileus, colonic diverticular disease, drug-related constipation, and chronic intestinal pseudo-obstruction. Expert opinion: Based on the added literature evidence, we feel that prucalopride is an effective, although expensive, drug for the treatment of primary and secondary forms of constipation, and of other clinical conditions associated with constipation.